- Home
- VVR vs TERN Comparison
VVR vs TERN Comparison
Compare VVR & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVR
- TERN
- Stock Information
- Founded
- VVR 1998
- TERN 2017
- Country
- VVR United States
- TERN United States
- Employees
- VVR N/A
- TERN N/A
- Industry
- VVR Trusts Except Educational Religious and Charitable
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- VVR Finance
- TERN Health Care
- Exchange
- VVR Nasdaq
- TERN Nasdaq
- Market Cap
- VVR 554.6M
- TERN 634.5M
- IPO Year
- VVR N/A
- TERN 2021
- Fundamental
- Price
- VVR $3.53
- TERN $7.40
- Analyst Decision
- VVR
- TERN Buy
- Analyst Count
- VVR 0
- TERN 6
- Target Price
- VVR N/A
- TERN $13.99
- AVG Volume (30 Days)
- VVR 692.2K
- TERN 1.1M
- Earning Date
- VVR 01-01-0001
- TERN 11-11-2025
- Dividend Yield
- VVR 11.38%
- TERN N/A
- EPS Growth
- VVR N/A
- TERN N/A
- EPS
- VVR N/A
- TERN N/A
- Revenue
- VVR N/A
- TERN N/A
- Revenue This Year
- VVR N/A
- TERN N/A
- Revenue Next Year
- VVR N/A
- TERN N/A
- P/E Ratio
- VVR N/A
- TERN N/A
- Revenue Growth
- VVR N/A
- TERN N/A
- 52 Week Low
- VVR $3.55
- TERN $1.87
- 52 Week High
- VVR $4.38
- TERN $10.70
- Technical
- Relative Strength Index (RSI)
- VVR 38.62
- TERN 59.10
- Support Level
- VVR $3.41
- TERN $7.01
- Resistance Level
- VVR $3.66
- TERN $7.67
- Average True Range (ATR)
- VVR 0.05
- TERN 0.42
- MACD
- VVR -0.01
- TERN -0.06
- Stochastic Oscillator
- VVR 48.00
- TERN 62.00
About VVR Invesco Senior Income Trust (DE)
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.